Reported Sunday, 23andMe Announced Nonclinical Data Supporting The Anti-tumor Activity Of 23Me-01473 Antibody Targeting NKG2D Ligand ULBP6, At The ESMO Congress
Portfolio Pulse from Benzinga Newsdesk
23andMe presented nonclinical data at the ESMO Congress showing the anti-tumor activity of its 23ME-01473 antibody, which targets the NKG2D ligand ULBP6. The antibody inhibited tumor growth in a mouse model of non-small cell lung cancer. Elevated ULBP6 levels were confirmed in certain carcinomas, suggesting potential clinical applications. A Phase 1 trial is ongoing, with the first patient dosed in March 2024.
September 16, 2024 | 9:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
23andMe's 23ME-01473 antibody shows promising preclinical results in inhibiting tumor growth in lung cancer models. The ongoing Phase 1 trial could lead to significant advancements in cancer treatment if successful.
The announcement of promising preclinical data for 23ME-01473 suggests potential future success in clinical trials, which could positively impact 23andMe's stock. The ongoing Phase 1 trial indicates progress in their drug development pipeline, which is crucial for investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90